Expected Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate General and administrative options expense [Member] Research and development options expense [Member] Restricted stock expense [Member] Statement of Income, Balance [Axis] Statement of Income, Balance [Domain] Total general and administrative expenses [Member] Total research and development expenses [Member] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Stockholders' Equity [Abstract] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Stock-Based Compensation Expense [Line Items] Pre Funded Warrants [Member] Pre-Funded Warrant [Member] Schedule Of Activity In Warrants Abstract Weighted Average Exercise Price, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Segments [Axis] Segment Reporting Information [Line Items] Segment research and development expenses Research and development expenses Research and Development Expense Total Operating Expenses Operating Expenses Other income (expenses) Other Nonoperating Income (Expense) Net Loss Net loss Other Income (Expense) Other Noncash Income (Expense) [Abstract] Segments [Domain] Number of reportable segment Number of Reportable Segments Total other income (expense) Nonoperating Income (Expense) Number of operating segment Number of Operating Segments Loss on equity method investment Change in value of equity method investment Income (Loss) from Equity Method Investments Acquired in process research and development Acquired In-Process Research and Development The amount of Acquired in-process research and development. Change in fair value of milestone warrant rights liability Change in fair value of milestone warrant rights liability Change in fair value of milestone warrant rights liability Fair Value Adjustment of Warrants Loss on extinguishment Loss on extinguishment of Azora Therapeutics convertible promissory notes Gain (Loss) on Extinguishment of Debt, Total License fees and milestone payments, description License Fees And Milestone Payments Description License fees and milestone payments, description. Weighted Average Exercise Price, Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Total Warrants, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsWarrantsExercised The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period. Total Warrants, Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsWarrantsExpired The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period. Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Total Warrants, Issued Restricted Stock, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted Average Exercise Price, Issued Weighted Average Grant Date Fair Value, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value CODM [Member] CODMMember Segment general and administrative expenses General and administrative expenses General and Administrative Expense Royalty expense Royalty Expense Segment Reporting [Abstract] Average Intrinsic Value, Outstanding Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value, Beginning Balance Total Warrants, Outstanding Ending Balance Restricted Stock Unvested, beginning Restricted Stock Unvested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Weighted Average Exercise Price, Outstanding Ending Balance Weighted Average Grant Date Fair Value Unvested, beginning Weighted Average Grant Date Fair Value Unvested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Remaining Term (Years), Outstanding Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Schedule of Activity in Warrants [Line Items] Class of Warrant or Right [Line Items] Warrant [Member] Warrants to purchase common shares [Member] Schedule of Fair Value of Consideration Transferred Fair Value of Consideration Transferred [Table Text Block] Tabular disclosure of Fair value of consideration transferred Schedule of Allocation to Estimated Fair Value of Consideration Transferred to Net Assets Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Conversion ratio Convertible Preferred Stock, Shares Issued upon Conversion Fair Value Measurements [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Business Combination [Abstract] Assets acquired: Business Combination, Recognized Asset Acquired, Asset [Abstract] Cash and cash equivalents Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Prepaid expenses Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current Total assets acquired Business Combination, Recognized Asset Acquired, Asset, Total Liabilities assumed: Business Combination, Recognized Liability Assumed, Liability [Abstract] Combined price Amount of combined price. Consideration transferred Total consideration transferred Business Combination, Consideration Transferred, Total Percentage of acquisition owned Business Combination, Voting Equity Interest Acquired, Percentage Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Securities Purchase Agreement [Member] Initial Closing Pre-Funded Warrant [Member] Exercise price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Aggregate shares Class of Warrant or Right, Outstanding Exchange Agreements [Member] Pre-Funded Warrants [Member] Convertible Preferred Stock [Abstract] Ownership [Axis] Business Combination [Axis] Business Combination [Domain] Adial’s Pipeline [Member] Aggregate purchase price Aggregate purchase price. Aggregate shares of company Aggregate shares of company. Ownership [Domain] Newly issued shares Newly issued shares Newly issued shares. CONVERTIBLE PREFERRED STOCK Preferred Stock [Text Block] Business Combination [Table] Shares issued Net proceeds from sale of common stock (in Shares) Stock Issued During Period, Shares, New Issues Class of Stock [Axis] RSUs [Member] Restricted Stock Units (RSUs) [Member] Schedule of Restricted Stock Units [Line Items] Restricted Stock, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted Stock, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Weighted Average Grant Date Fair Value, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 2,625,890 and 1,111,010 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Fair Value Measurement Inputs and Valuation Techniques [Table] Schedule of Fair Value of the Milestone Warrant Liability [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input Measurement Input Type [Axis] Measurement Input Type [Domain] Underlying Stock Price [Member] Measurement Input, Share Price [Member] Risk-Free Interest Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Expected Volatility [Member] Measurement Input, Price Volatility [Member] Exercise Price [Member] Measurement Input, Exercise Price [Member] Expected Dividend Yield [Member] Measurement Input, Expected Dividend Rate [Member] Expected Term (Years) [Member] Measurement Input, Expected Term [Member] Probability of Milestone Achievement [Member] Measurement Input, Probability of Milestone Achievement [Member] Schedule of Milestone Warrant Liability Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Balance at Beginning of Period Balance at End of Period Derivative Liability, Current Document Fiscal Year Focus Document Information [Line Items] Document Information [Table] Document Period End Date Document Transition Report Document Type Entity Address, Address Line One Accumulated deficit Retained Earnings (Accumulated Deficit) Statement [Line Items] Statement of Financial Position [Abstract] Statement [Table] Total Stockholders’ (Deficit) Equity Balance Balance Equity, Attributable to Parent Stockholders’ (Deficit) Equity Equity, Attributable to Parent [Abstract] Initial fair value of Milestone warrant rights issued Initial Fair Value of Warrants Issued Amount of initial fair value of warrants issued. Change in fair value recognized in other income (expenses) Change in Fair Value Recognized in Net Loss Amount of change in fair value recognized in net loss. Warrants exercised / settled during the period Warrants Exercised or Settled During the Period Amount of warrants exercised / settled during the period. Defined Benefit Plan [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 3 Milestone Warrant Liability [Member] Fair Value, Inputs, Level 3 [Member] Schedule of Milestone Warrant Liability [Line Items] Defined Benefit Plan Disclosure [Line Items] Financing Expense Related To Milestone Warrant Rights Liability Financing Expense Related To Milestone Warrant Rights Liability Financing Expense Related To Milestone Warrant Rights Liability Financing Expense Related To Milestone Warrant Rights Liability The amount of financing expense related to milestone warrant rights liability. Fair value of assumed options that relates to the pre-combination service period Adjustments to Additional Paid in Capital, Fair Value Issuance costs from the private placement issuance of pre-funded warrants Payments for Repurchase of Private Placement Convertible Preferred Stock Preferred Stock, Redeemable [Policy Text Block] Net liabilities acquired in the acquisition of Azora Therapeutics Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total Exercise of warrants, net of expenses Stock Issued During Period, Value, Stock Options Exercised Exercise of warrants, net of expenses (in Shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance costs from the private placement issuance of pre-funded warrants included in accounts payable Issuance Costs from the Private Placement Issuance of Pre-funded Warrants Included in Accounts Payable The amount of issuance costs from the private placement issuance of pre-funded warrants included in accounts payable. Accumulated Deficit Retained Earnings [Member] Balance (in Shares) Balance (in Shares) Shares, Outstanding Equity-based compensation - stock issuances to vendors Adjustments to Additional Paid in Capital Stock Issuances to vendor Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in stock issuances to vendor. Equity Components [Axis] Shares issued from abeyance (in shares) Stock Issued During Period, Shares, Other Equity-based compensation - stock issuances to a vendor and vesting to employee (in Shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total Equity-based compensation - stock issuances to a vendor and vesting to employee Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total Statement of Stockholders' Equity [Abstract] Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Non-FDIC insured cash equivalent Cash, Uninsured Amount Convertible preferred stock, par value Preferred Stock, par value (in Dollars per share) Preferred Stock, Par or Stated Value Per Share Total potentially dilutive Common Shares excluded Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Schedule of Potentially Dilutive Common Shares [Line Items] Antidilutive Securities, Name [Domain] Schedule of Potentially Dilutive Common Shares [Abstract] Common Stock [Member] Common stock issued [Member] Common Stock Common Stock [Member] Fair Value Measurements [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Preferred stock, shares authorized (in Shares) Preferred Stock, Shares Authorized Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accrued Expenses [Abstract] STOCKHOLDERS' EQUITY Shareholders' Equity and Share-Based Payments [Text Block] Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Statement of Cash Flows [Abstract] Shares issued from abeyance Stock Issued During Period, Value, Other Weighted average shares, diluted Weighted Average Number of Shares Outstanding, Diluted Other Income (Expense) Nonoperating Income (Expense) [Abstract] Basic and Diluted Loss per Share Earnings Per Share, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Class of Stock [Domain] FDIC insured cash amount Cash, FDIC Insured Amount Going Concern and Other Uncertainties [Abstract] Reverse Stock Split [Member] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Equity Method Investments Equity Method Investments [Policy Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Equity-based compensation – restricted stock (in Shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Issuance of pre-funded warrants in connection with the private placement transaction Stock Issued During Period Value Issuance of Pre-Funded Warrants in Connection With Private Placement Transaction Amount of Issuance of pre-funded warrants in connection with private placement transaction Issuance of Series A convertible preferred stock in connection with the acquisition of Azora Therapeutics Stock Issued During Period Value Issuance of Series A Redeemable Convertible Preferred Stock and Common Stock Amount of Issuance of Series A redeemable convertible preferred stock and common stock Issuance of Series A convertible preferred stock in connection with the acquisition of Azora Therapeutics (in Shares) Stock Issued During Period Shares Issuance of Series A Redeemable Convertible Preferred Stock and Common Stock The Number of Issuance of Series A redeemable convertible preferred stock and common stock Issuance of Series A Redeemable Convertible Preferred Stock and Common Stock Debt Instrument [Axis] Debt Instrument, Name [Domain] Percentage of outstanding equity Debt, Weighted Average Interest Rate Temporary Equity Series A Convertible Preferred Stock Temporary Equity Series A Convertible Preferred Stock [Member] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] EQUITY METHOD INVESTMENTS Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Method Investments [Abstract] Commitments and Contingencies [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Supplemental disclosure of noncash financing information: Supplemental Cash Flow Information [Abstract] DESCRIPTION OF BUSINESS Business Description and Basis of Presentation [Text Block] Description of Business [Abstract] Plan Name [Axis] Plan Name [Domain] Total Options Outstanding, Outstanding at beginning Total Options Outstanding, Outstanding at ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance Weighted Average Exercise Price, Outstanding ending Weighted Average Exercise Price, Outstanding beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted Average Remaining Term (Years), Outstanding ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Term (Years),Outstanding, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Exercise Price, Outstanding, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share option granted Total Options Outstanding, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Total Options Outstanding, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Common stock, shares Outstanding (in Shares) Common Stock, Shares, Outstanding Exchange ratio Debt Instrument, Convertible, Conversion Ratio Number of shares vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Azora Therapeutics [Member] Exercise price Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Beginning Balance Stock Option [Member] Inducement Grants [Member] Portion of operating losses recognized Portion Of Operating Losses Recognized The net result for the period of deducting operating expenses from operating revenues. Share of dilution to new investors Proportionate Share Of Dilution To New Investors Amount of proportionate share of dilution to new investors. Equity investment carrying amount, ending balance Equity method investment Equity investment carrying amount, beginning balance Equity Method Investments RSAs [Member] Restricted Stock Award [Member] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units and Awards [Member] Sold amount Sale of Stock, Consideration Received on Transaction Sale of stock Sale of Stock, Number of Shares Issued in Transaction Stock, Class of Stock [Table] Number of shares authorized for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Outstanding options intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Number of shares issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Equity issuance cost Payments of Stock Issuance Costs Related and Nonrelated Parties [Axis] Newly issued share Newly issued share Newly issued share. Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] Schedule of Segment Reporting Information, by Segment [Table] Operating Expenses: Operating Expenses [Abstract] Loss From Operations Operating Income (Loss) Interest income Investment Income, Interest Schedule of Significant Segment Expenses [Abstract] Class of Warrant or Right [Table] Accrued expenses Accrued Liabilities Accounts payable and accrued liabilities Business Combination, Recognized Liability Assumed, Accounts Payable, Current Total liabilities assumed Business Combination, Recognized Liability Assumed, Liability, Total Net assets acquired Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), Total Compensation and employee benefits liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Compensation and Employee Benefits Liabilities Amount of compensation and employee benefits liabilities. Convertible promissory notes Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Convertible Promissory Notes Amount of convertible promissory notes. In process research and development Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research and Development Amount of in process research and development. Business Combination, Consideration Transferred, Equity Interest [Table] Business Combination, Consideration Transferred, Equity Interest, Type [Axis] Business Combination, Consideration Transferred, Equity Interest, Type [Domain] Schedule of Fair Value of Consideration Transferred [Line Items] Business Combination, Consideration Transferred, Equity Interest [Line Items] Series A preferred stock issued [Member] Series A Preferred Stock [Member] Series A Assumed options [Member] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Acquisition of Azora and Pipe Issuance [Line Items] Business Combination [Line Items] Azora Therapeutics, LLC [Member] Conversion of common stock Conversion of Stock, Shares Issued Convertible Common Stock [Member] Series A Preferred Stock Series A convertible preferred stock, shares authorized (in Shares) Temporary Equity, Shares Authorized Acquisition of Azora and Pipe Issuance [Abstract] Series A Preferred Stock, par value Series A convertible preferred stock, par value (in Dollars per share) Temporary Equity, Par or Stated Value Per Share ACQUISITION OF AZORA AND PIPE ISSUANCE Acquisition of Azora and Pipe Issuance [Text Block] The entire disclosures of Acquisition of azora and pipe issuance Convertible Preferred Stock [Line Items] Class of Stock [Line Items] Preferred Stock [Member] Convertible preferred stock Preferred Stock, Convertible, Shares Issuable Preferred shares issued Series A convertible preferred stock, shares issued (in Shares) Temporary Equity, Shares Issued Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total Liabilities Liabilities Common Stock, par value (in Dollars per share) Common stock price Common Stock, Par or Stated Value Per Share Common Stock, shares authorized (in Shares) Number of shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Entity Interactive Data Current Document Quarterly Report City Area Code Cover [Abstract] Current Fiscal Year End Date Accrued expenses Total accrued expenses Accrued Liabilities, Current Current Assets: Assets, Current [Abstract] Cash and cash equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Commitments and contingencies – see Note 10 Commitments and Contingencies Percentage of merger owned Subsidiary, Ownership Percentage, Parent Entity Emerging Growth Company Loss per share, basic Earnings Per Share, Basic Loss per share, diluted Earnings Per Share, Diluted Entity Registrant Name Entity Shell Company Entity Small Business Entity Tax Identification Number Local Phone Number Series A convertible preferred stock, shares outstanding (in Shares) Temporary Equity, Shares Outstanding Price per share Shares Issued, Price Per Share Principal amount Debt Instrument, Issued, Principal Total Assets Assets Total Current Assets Assets, Current Income Statement [Abstract] Total Liabilities, Temporary Equity and Stockholders’ (Deficit) Equity Liabilities and Equity Total Current Liabilities Liabilities, Current Current Liabilities: Liabilities, Current [Abstract] Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share as of June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Entity Filer Category Entity Incorporation, State or Country Code Additional paid in capital Additional Paid in Capital Schedule of Fair Value of the Milestone Warrant Liability Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Title of 12(b) Security Security Exchange Name Trading Symbol Entity File Number Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Entity Current Reporting Status Accounts payable Accounts Payable, Current Amendment Flag Milestone warrant rights liability Derivative Liability, Noncurrent Series A convertible preferred stock, $0.001 par value; 13,000 and 0 shares designated as of June 30, 2026 and December 31, 2025, respectively; 12,930.617 and 0 shares issued and outstanding as of June 30 2026 and December 31, 2025, respectively Temporary Equity, Carrying Amount, Attributable to Parent ASSETS Assets [Abstract] LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ (DEFICIT) EQUITY Liabilities and Equity [Abstract] Series A redeemable convertible preferred stock Redeemable Preferred Stock [Member] Weighted Average Grant Date Fair Value, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Net proceeds from sale of common stock Stock Issued During Period, Value, New Issues Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Weighted average shares, basic Weighted Average Number of Shares Outstanding, Basic Schedule of Activity in Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Accounts payable, related party Increase (Decrease) in Due from Related Parties Fair value of Series A convertible preferred stock issued for the acquisition of Azora Therapeutics Stock Issued GOING CONCERN AND OTHER UNCERTAINTIES Substantial Doubt about Going Concern [Text Block] Net cash assumed in the acquisition of Azora Therapeutics Net Cash Assumed in the Acquisition of Azora Therapeutics The amount of net cash assumed in the acquisition of azora therapeutics. Percentage of weighted average equity Percentage of weighted average equity. Proceeds from the private placement issuance of pre-funded warrants Proceeds from Issuance of Private Placement Schedule of Restricted Stock Units Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Proceeds from warrant exercise, net of expenses Proceeds from Warrant Exercises Equity-based compensation – restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Going Concern And Other Uncertainties [Table] Going Concern And Other Uncertainties [Line Items] Extinguishment of the Azora Therapeutics convertible promissory notes to pre-funded warrants Conversion of the Azora Therapeutics Convertible Promissory Notes to Pre-funded Warrants The amount of conversion of the azora therapeutics convertible promissory notes to pre-funded warrants. Series A Non-Voting Convertible Preferred Stock Convertible Preferred Stock [Member] Unvested restricted stock [Member] Restricted Stock [Member] Antidilutive Security, Excluded EPS Calculation [Table] Common Shares issuable on exercise of options [Member] Equity Option [Member] Other income Other Income Equity Method Investment [Table] Equity Method Investments [Line Items] Additional Paid In Capital Additional Paid-in Capital [Member] Equity-based compensation - stock option expense APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Issuance of common stock in connection with the acquisition of Azora Therapeutics (in Shares) Stock Issued During Period, Shares, Acquisitions Issuance of common stock in connection with the acquisition of Azora Therapeutics Stock Issued During Period, Value, Acquisitions Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Milestone warrant rights liability Milestone Rights Liability [Policy Text Block] Disclosure of accounting policy for milestone rights liability. Volume weighted average stock price rate Volume Weighted Average Stock Price Rate Percentage of volume weighted average stock price rate. Purchase price Sale of Stock, Price Per Share Probability of achieving Probability of Achieving Rate of probability of achieving. Fair Value, Recurring and Nonrecurring [Table] Net proceeds from sale of common stock Proceeds from Issuance of Common Stock Equity Component [Domain] Cash receipt from contingent consideration Cash Receipt From Contingent Consideration The amount of cash receipt from contingent consideration. Change in fair value contingent consideration Change In Fair Value Contingent Consideration The amount of changes in fair value contingent consideration. Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Basis of Presentation and Summary of Significant Accounting Policies [Line Items] Product Information [Line Items] Summary of Significant Accounting Policies [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Transaction costs for the acquisition of Azora Therapeutics in accounts payable and accrued liabilities Liabilities Assumed Right to purchase Milestone warrants in association with the private placement issuance of the pre-funded warrants Right to Purchase Milestone Warrants in Association with the Private Placement Issuance of the Pre-Funded Warrants The amount of right to purchase milestone warrants in association with the private placement issuance of the pre-funded warrants Employee compensation Deferred Compensation Equity Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] CODM description Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Reverse stock split Stockholders' Equity, Reverse Stock Split Adovate’s equity [Member] Purnovate, Inc. [Member] Purnovate Inc Member Investment, Name [Domain] Investment, Name [Axis] Reverse Stock Split Reverse Stock Split [Policy Text Block] Disclosure policy of reverse stock split. Schedule of Significant Segment Expenses Segment Reporting, Reconciliation of Revenue by Segment to Consolidated [Table Text Block] Schedule of Potentially Dilutive Common Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Incorporated date Entity Incorporation, Date of Incorporation Schedule of Equity Method Investment Equity Method Investments [Table Text Block] Schedule of Black Scholes Valuation Model to Determine the Fair Value of the Options Issued Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Asset Class [Domain] Asset Class [Axis] Schedule of Equity Method Investment [Line Items] Pre-clinical and manufacturing expenses Preclinical And Manufacturing Expenses Amount of pre-clinical and manufacturing expenses. Schedule of Accrued Expenses [Abstract] Legal and consulting expense Accrued Professional Fees, Current Minimum license royalties Accrued Royalties, Current Other Other Accrued Liabilities, Current Employee compensation Workers' Compensation Liability, Current At-the-Market Offering Agreement 2025 [Member] Atthe Market Offering Agreement Twenty Twenty Five [Member] Schedule Of Equity Method Investment Abstract Equity Method Investments [Member] Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Shareholders’ Equity [Line Items] Recognized over a weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Weighted Average Exercise Price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Related and Nonrelated Parties [Domain] Related Party [Member] Former Azora Stockholders [Member] Fixed commission rate on sale of common stock Fixed Commission Rate On Sale Of Common Stock Percentage of fixed commission rate on sale of common stock. Total Options Outstanding, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Schedule of Stock Option Activity [Abstract] Standby Equity Purchase Agreement [Member] Standby Equity Purchase Agreement Member 2017 Equity incentive Plan [Member] Two Thousand Seventeen Equity Incentive Plan Member Schedule of Black Scholes Valuation Model to Determine the Fair Value of the Options Issued [Abstract] Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Expected Dividend Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Chief Executive Officer